Buprenorphine (Pain)
buprenorphine hydrochloride — Butrans (transdermal), Belbuca (buccal film), Buprenex (injection)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate-to-severe chronic pain requiring continuous around-the-clock opioid (Butrans transdermal) | Adults | Monotherapy | FDA Approved |
| Severe and persistent pain requiring around-the-clock opioid when alternatives are inadequate (Belbuca buccal film) | Adults | Monotherapy | FDA Approved |
| Moderate-to-severe acute pain (Buprenex injection) | Adults; children ≥2 y | Monotherapy or adjunctive | FDA Approved |
Buprenorphine occupies a unique pharmacological position among opioid analgesics. As a partial agonist at the mu-opioid receptor with very high binding affinity, it provides effective analgesia while exhibiting a ceiling effect on respiratory depression — a safety advantage not shared by full mu-agonists such as morphine, oxycodone, or fentanyl. This makes buprenorphine particularly suitable for patients with comorbidities that increase respiratory depression risk (COPD, sleep apnoea, elderly, concurrent CNS depressants) and for patients in whom clinicians wish to mitigate overdose risk. Buprenorphine is classified as Schedule III, reflecting its lower abuse potential relative to Schedule II opioids. Importantly, the pain-indication formulations (Butrans, Belbuca, Buprenex) do not require an X-waiver or special DEA registration — these requirements applied only to addiction-treatment formulations and were eliminated in 2023.
Neuropathic pain (chronic) — Growing evidence supports buprenorphine’s efficacy in neuropathic pain, potentially mediated by its kappa-antagonist and ORL-1 agonist activity. Evidence quality: Moderate.
Rotation from high-dose full mu-agonist opioids — Used to transition patients from problematic long-term full-agonist opioid therapy to a safer opioid with ceiling effect. Evidence quality: Moderate (VA/DoD clinical guidance).
This monograph focuses on buprenorphine formulations approved for pain management (Butrans, Belbuca, Buprenex). Buprenorphine/naloxone (Suboxone) and buprenorphine sublingual/injection formulations approved for opioid use disorder (OUD) are covered in a separate monograph.
Dosing
Belbuca (Buccal Film) — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic pain — opioid-naive or low-dose opioid (<30 mg MSE/day) | 75 mcg buccal qDay or q12h for ≥4 days | Increase to 150 mcg q12h; then titrate by 150 mcg q12h q4 days | 450 mcg q12h (opioid-naive max studied) | Apply film to inner cheek; let dissolve fully (do not chew or swallow); doses 600–900 mcg only after titration from lower doses Avoid liquids during film application; reduce dose by half in mucositis (FDA PI) |
| Chronic pain — converting from 30–89 mg MSE/day | 150 mcg buccal q12h | Titrate by 150 mcg q4 days | 900 mcg q12h | Taper prior opioid to ≤30 mg MSE/day before starting Belbuca to reduce precipitated withdrawal risk Supplement with short-acting analgesic during taper and titration |
| Chronic pain — converting from 90–160 mg MSE/day | 300 mcg buccal q12h | Titrate by 150 mcg q4 days | 900 mcg q12h | Higher starting dose; monitor for withdrawal during transition Do NOT exceed 900 mcg q12h due to QTc prolongation risk (Belbuca PI) |
Butrans (Transdermal 7-Day Patch) — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic pain — opioid-naive | 5 mcg/h patch q7days | Titrate q72h (min 3 days on each dose) | 20 mcg/h | Apply to non-hairy, intact skin (upper chest, back, upper arm); rotate sites 5 mcg/h ≈ 9–13 MME/day; suitable for opioid-naive patients (FDA PI) |
| Chronic pain — converting from <80 mg oral morphine/day | 5–10 mcg/h patch q7days | Titrate by 5 mcg/h q72h | 20 mcg/h | Taper prior opioid; some precipitated withdrawal possible during transition Analgesic effect takes 12–24 h to develop; provide IR opioid coverage initially |
Buprenex (Injection) — Acute Pain
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute moderate-to-severe pain — adults | 0.3 mg IM or slow IV q6h | 0.3 mg q6h PRN | 0.6 mg per dose | IV: administer slowly over ≥2 minutes 30–60 min to peak effect IM; may repeat once after 30–60 min if needed |
| Acute pain — children 2–12 years | 2–6 mcg/kg IM or slow IV q4–6h | 2–6 mcg/kg q4–6h | 6 mcg/kg per dose | Limited paediatric data Not recommended for children <2 years (Buprenex PI) |
Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hepatic impairment (moderate/severe) | Reduce starting dose; use half initial dose for Belbuca in severe | Titrate cautiously | Reduce proportionally | Plasma levels and t½ increased in moderate/severe impairment; monitor for toxicity Buprenorphine is hepatically metabolised; LFT monitoring recommended |
| Renal impairment | No adjustment required | Standard dosing | Standard | Primarily faecal elimination; no accumulation in renal failure; not dialysable Buprenorphine PK unchanged in haemodialysis patients (FDA PI) |
| Elderly (≥65 years) | Use lowest available dose | Titrate slowly | Standard | Higher incidence of constipation, respiratory depression, urinary retention in elderly No PK-based adjustment needed; clinical caution required |
Buprenorphine’s high mu-receptor affinity means it can displace full mu-agonists (morphine, oxycodone, fentanyl) from receptors, precipitating acute withdrawal in opioid-dependent patients. When converting from a full agonist, taper the prior opioid dose to ≤30 mg MSE/day before initiating buprenorphine. If using Butrans patches for conversion, the patch can sometimes be applied before full discontinuation of the prior opioid due to its gradual onset, but monitor closely for withdrawal signs.
Unlike full mu-agonists, buprenorphine exhibits a ceiling effect on respiratory depression at approximately 0.1–0.4 mg IV doses, beyond which increasing doses produce minimal additional respiratory depression. This property provides a significant safety margin, particularly valuable in patients with COPD, sleep apnoea, concurrent benzodiazepine use, or advanced age. However, respiratory depression can still occur, especially when buprenorphine is combined with other CNS depressants. The analgesic effect does NOT show a ceiling at clinically used doses.
Pharmacology
Mechanism of Action
Buprenorphine is a semi-synthetic thebaine derivative with a uniquely complex receptor pharmacology. It functions as a partial agonist at the mu-opioid receptor (MOR) with exceptionally high binding affinity (Ki ~1 nM) and very slow receptor dissociation kinetics. This partial agonism means that buprenorphine activates the MOR sufficiently to provide clinically effective analgesia, but with a lower maximal efficacy than full agonists, resulting in a ceiling effect on respiratory depression. Buprenorphine also acts as an antagonist at the kappa-opioid receptor (KOR), which may contribute to its anti-dysphoric and potentially anti-depressant properties, and as an agonist at the ORL-1 (nociceptin/orphanin FQ) receptor, which modulates pain processing at the spinal level. Additionally, buprenorphine demonstrates NMDA receptor antagonist activity, which may contribute to efficacy in neuropathic pain states and reduce opioid-induced hyperalgesia. Its high receptor affinity means that buprenorphine is difficult to displace by other opioids, and conversely, it can displace full agonists from the receptor, which underlies its ability to precipitate withdrawal in opioid-dependent patients receiving full mu-agonists.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability <5% (extensive first-pass); SL ~29%; buccal (Belbuca) 46–65%; transdermal ~15% (effective rate); IV 100%; Tmax: buccal 2.5–3 h; transdermal 60–72 h to steady state; IV ~2 min onset | Oral route not viable; buccal film offers highest non-parenteral bioavailability; transdermal provides very gradual onset (12–24 h to therapeutic levels); do not ingest liquids during buccal film application (reduces bioavailability by 23–27%) |
| Distribution | Vd 188–335 L (IV); highly lipophilic; protein binding ~96% (alpha/beta-globulins); rapidly penetrates blood-brain barrier | High protein binding means that in hypoproteinaemic states (liver disease, malnutrition), free drug fraction may increase; lipophilicity enables effective transdermal absorption and rapid CNS penetration |
| Metabolism | Hepatic N-dealkylation via CYP3A4/3A5 (primary; 80–90%) to norbuprenorphine (active metabolite, weak analgesic but potent respiratory depressant); also CYP2C8 contribution; both parent and metabolite undergo glucuronidation via UGT1A1, UGT2B7, UGT1A3 | CYP3A4 interactions are clinically significant (FDA Boxed Warning); norbuprenorphine has ~1/50th analgesic potency but is a full MOR agonist with respiratory depressant activity (normally limited by P-glycoprotein restriction of CNS access) |
| Elimination | t½ 20–73 h (mean ~37 h SL); primarily faecal (>70%) via biliary excretion with enterohepatic recirculation; renal ~10–30% (conjugated metabolites); <5% unchanged in urine | Long half-life supports q12h (buccal) and q7day (transdermal) dosing; faecal elimination means NO dose adjustment in renal impairment; enterohepatic recirculation contributes to prolonged duration of action; not dialysable due to high protein binding and molecular weight |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 21–23% | Most common AE; dose-related; typically improves within 1–2 weeks of stable dosing; higher in opioid-naive patients |
| Headache | 16% | Common across both Butrans and Belbuca; usually self-limiting |
| Application site pruritus (Butrans) | 15% | Most common patch-specific reaction; usually mild; rotate application sites; antihistamine cream may help |
| Constipation | 13–14% | Lower than with full mu-agonists at equianalgesic doses; still requires prophylactic bowel regimen for chronic use |
| Dizziness | 10% | Orthostatic component; advise slow position changes; generally improves with tolerance |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 6–9% | More common during initiation; anti-emetic prophylaxis may be considered |
| Application site erythema (Butrans) | 7% | Usually mild and resolves after patch removal; rotate sites weekly |
| Somnolence | 5% | Lower sedation rate than full mu-agonists; warn about driving/machinery |
| Fatigue | 5% | Dose-related; usually improves with stable dosing |
| Dry mouth | 5% | Encourage oral hydration; dental hygiene important (FDA dental advisory for all buprenorphine products) |
| Peripheral oedema | 3% | Evaluate for other causes; more common in chronic use |
| Pruritus (systemic) | 2–4% | Opioid class effect; may respond to antihistamines |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Respiratory depression | Rare (ceiling effect provides safety margin) | Initiation or with CNS depressant co-administration | Higher doses of naloxone may be required due to buprenorphine’s high receptor affinity; prolonged monitoring needed given long t½; ventilatory support |
| QTc prolongation (Belbuca) | Dose-related at >900 mcg BID | Any time; dose-dependent | Do not exceed 900 mcg BID; ECG monitoring if risk factors present; avoid with other QTc-prolonging drugs |
| Hepatotoxicity / Elevated LFTs | Uncommon | Variable; weeks to months | Baseline LFTs; periodic monitoring; spectrum ranges from transient transaminase elevations to hepatic failure (primarily reported with SL formulations for OUD) |
| Precipitated withdrawal | Common if converted from full agonist without adequate taper | Within hours of first buprenorphine dose | Taper prior full agonist to ≤30 mg MSE/day before initiation; symptomatic treatment with clonidine, anti-emetics, anti-diarrhoeals |
| Adrenal insufficiency | Rare | Chronic use (>1 month) | Morning cortisol; physiologic corticosteroid replacement; opioid taper |
| Serotonin syndrome | Rare | With serotonergic co-medications | Discontinue buprenorphine and serotonergic agent; supportive care |
| Anaphylaxis / Hypersensitivity | Rare (post-marketing) | Any time | Epinephrine; permanent discontinuation; includes bronchospasm, angioedema |
| NOWS | Expected with prolonged maternal use (milder than full agonists) | Within days of delivery | Neonatology team; neonatal scoring and treatment; buprenorphine-associated NOWS generally milder than with full agonists |
Due to buprenorphine’s exceptionally high receptor binding affinity and slow dissociation kinetics, standard doses of naloxone (0.4–2 mg) may be insufficient to reverse respiratory depression. Higher naloxone doses (10–35 mg has been reported) and/or continuous naloxone infusion may be required. Given buprenorphine’s long half-life (20–73 h), monitor for recurrence of respiratory depression for at least 24–48 hours after reversal. Mechanical ventilation should be readily available.
Drug Interactions
Buprenorphine is metabolised primarily by CYP3A4, making it susceptible to pharmacokinetic interactions with CYP3A4 inhibitors and inducers. However, at therapeutic concentrations, buprenorphine does not significantly inhibit or induce CYP enzymes, minimising its effect on other drugs. Its partial agonist pharmacology creates unique pharmacodynamic interactions with other opioids.
Monitoring
- Respiratory RateInitiation and dose changes
RoutineCeiling effect provides safety margin but does not eliminate risk. Particularly important when combined with CNS depressants. Monitor for at least 24 h after initiation of IV buprenorphine. - Pain AssessmentEvery visit
RoutineValidated pain scales; functional outcomes. Assess for adequate analgesia and dose optimisation. - Liver Function TestsBaseline; periodically
RoutineBaseline LFTs for patients at increased hepatotoxicity risk (alcohol use, IV drug use history, hepatitis B/C, liver disease). Monitor periodically during chronic use. Spectrum from asymptomatic transaminase elevations to rare hepatic failure. - Withdrawal SignsDuring conversion from full agonist
Trigger-basedMonitor for precipitated withdrawal when transitioning from full mu-agonists. Use COWS (Clinical Opiate Withdrawal Scale) to quantify severity. Higher risk if prior opioid not adequately tapered. - ECG / QTcIf using Belbuca ≥600 mcg BID or risk factors
Trigger-basedQTc prolongation is dose-dependent with Belbuca; risk increases above 900 mcg BID (the approved maximum). Obtain ECG if concurrent QTc-prolonging medications, electrolyte abnormalities, or personal/family history of long QT. - Patch Site (Butrans)Every patch change (weekly)
RoutineInspect for erythema, pruritus, vesicles, or severe skin reactions. Rotate application sites. Rare severe reactions with marked inflammation reported. - Aberrant BehaviourBefore initiation and ongoing
RoutinePDMP checks; UDS per protocol. Note: buprenorphine may not appear on standard opioid immunoassay screens; requires specific buprenorphine assay or GC-MS confirmatory testing. - Dental HealthBaseline; periodically
Trigger-basedFDA dental advisory (2022) for all buprenorphine products dissolved in the mouth: risk of dental caries, tooth loss, and gingival recession. Recommend regular dental examinations and good oral hygiene.
Contraindications & Cautions
Absolute Contraindications
- Significant respiratory depression in unmonitored settings
- Acute or severe bronchial asthma in unmonitored environment
- Known or suspected paralytic ileus or GI obstruction
- Hypersensitivity (anaphylaxis) to buprenorphine or any component
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment — increased buprenorphine levels and prolonged t½; dose reduction required; monitor for toxicity
- Patients on high-dose full mu-agonist opioids (>160 mg MSE/day) — conversion to buprenorphine at these doses has high precipitated-withdrawal risk and uncertain analgesic equivalence; specialist guidance recommended
- QTc prolongation risk factors (Belbuca) — personal/family history of long QT, concurrent QTc-prolonging drugs, electrolyte abnormalities
- Oral mucositis (Belbuca) — increased absorption may lead to supratherapeutic levels; dose reduction required
Use with Caution
- Elderly or debilitated patients — higher incidence of constipation, respiratory depression, urinary retention
- COPD or respiratory compromise — ceiling effect provides relative safety but does not eliminate risk
- Head injury or raised ICP — may obscure neurological assessment
- History of hepatotoxicity or hepatitis B/C — baseline and periodic LFT monitoring
- Biliary tract disease — sphincter of Oddi spasm possible
- Seizure disorders — may lower seizure threshold
Buprenorphine exposes users to risks of opioid addiction, abuse, and misuse leading to overdose and death. Serious respiratory depression may occur despite the ceiling effect, especially during initiation, dose increase, or concurrent CNS depressant use. Concomitant CYP3A4 inhibitors (or discontinuation of inducers) may cause fatal accumulation. Accidental exposure, especially in children, can be fatal. Prolonged use in pregnancy causes NOWS.
Patient Counselling
Purpose of Therapy
Buprenorphine is a strong pain medication that works differently from traditional opioid painkillers. It partially activates the pain-relief system in your body, providing effective pain control while having a built-in safety ceiling on its most dangerous side effect — slowed breathing. This makes it a safer option for many patients compared to other strong painkillers, while still providing meaningful pain relief.
How to Use
Belbuca buccal film: Place the film on the inside of your cheek (where the cheek meets the gum) and let it dissolve completely. Do not chew, swallow, or spit out the film. Avoid drinking liquids while the film is dissolving. Use twice daily at approximately the same times. Butrans patch: Apply to a non-hairy, dry area of intact skin on the upper chest, upper back, or upper outer arm. Press firmly for 15 seconds. Change every 7 days, using a different site each time. You may shower with the patch on.
Sources
- Belbuca (buprenorphine buccal film) — Full prescribing information (Collegium Pharmaceutical). FDA/Drugs@FDA. FDA LabelPrimary reference for buccal film dosing, QTc prolongation warning, conversion from prior opioids, and AE rates from Phase III trials.
- Butrans (buprenorphine transdermal system) — Full prescribing information (Purdue Pharma). FDA/Drugs@FDA. FDA LabelSource for transdermal patch dosing (5–20 mcg/h), 7-day application schedule, application site reaction rates, and opioid conversion guidance.
- Buprenex (buprenorphine injection) — Full prescribing information (Indivior). FDA/Drugs@FDA. FDA LabelInjectable formulation reference for acute pain dosing (0.3 mg q6h), paediatric dosing (2–6 mcg/kg), and IV administration guidance.
- Gimbel J, Spierings EL, Katz N, Xiang Q, et al. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain. Pain. 2016;157(11):2517–2526. doi:10.1097/j.pain.0000000000000670Pivotal Phase III EERW trial of Belbuca in opioid-experienced chronic low back pain patients demonstrating efficacy and GI tolerability.
- Rauck RL, Potts J, Xiang Q, Tzanis E, et al. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1–11. doi:10.1080/00325481.2016.1128307Phase III trial establishing Belbuca efficacy in opioid-naive patients with chronic low back pain; source for opioid-naive AE rates.
- Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain. J Pain. 2011;12(11):1163–1173. doi:10.1016/j.jpain.2011.06.003Key Butrans efficacy trial in chronic low back pain demonstrating superiority over placebo with 7-day patch application.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(RR-3):1–95. doi:10.15585/mmwr.rr7103a1Current CDC guideline on opioid prescribing; acknowledges buprenorphine’s ceiling-effect safety advantage and Schedule III classification.
- VA/DoD National Pain Management, Opioid Safety, and PDMP Program Office. Buprenorphine for Management of Chronic Pain — Clinical Guidance. 2024. VA Clinical GuidanceComprehensive VA/DoD guidance on buprenorphine for chronic pain including rotation from full agonists, safety advantages, and formulation comparisons.
- Raffa RB, Haidery M, Huang HM, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39(6):577–583. doi:10.1111/jcpt.12196Addresses the misconception of an analgesic ceiling effect; demonstrates that clinical analgesia does not plateau at therapeutic doses.
- Khanna IK, Pillarisetti S. Buprenorphine — an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–870. doi:10.2147/JPR.S85951Review of buprenorphine’s multi-receptor pharmacology (partial MOR agonist, KOR antagonist, ORL-1 agonist, NMDA antagonist) and clinical advantages.
- Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–680. doi:10.2165/00003088-200544070-00001Comprehensive PK review establishing Vd, protein binding (96%), t½ range (3–44 h), CYP3A4 metabolism, and faecal elimination pathway.
- Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011;115(6):1251–1260. doi:10.1097/ALN.0b013e318238fea0Key study characterising the pharmacological activity of buprenorphine glucuronide metabolites, relevant to understanding the drug’s complex pharmacology.
- Kumar R, Viswanath O, Saadabadi A. Buprenorphine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jun 8. NCBI BookshelfStatPearls reference covering buprenorphine pharmacology across all formulations and indications (pain and OUD).